ISInass Shaltout

Inass Shaltout

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Inass Shaltout has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incretins beyond weight and hyperglycemia management: a consensus statement by AASD

    by Inass Shaltout, Mona Hegazy, Amr Abdel Hady El Meligi, Shereen Abdelghaffar, Mohamed-Naguib Wifi, Alia A. Saleh, Hany Hammad, Amany Atef el Karim Abouzeid, Ebtesam Fahmy, Gehad Maghraby, et al.

    Background: The global prevalence of obesity continues to rise, with 3 billion adults projected to be affected by 2030. Recent advances in anti-obesity pharmacotherapy, particularly incretin-based medications, have transformed obesity management. This consensus provides evidence-based guidelines for the clinical use of incretin-based obesity management medications (OMMs). Methods: This consensus was developed through consensus narrative review and expert panel deliberation, examining current evidence for approved anti-obesity medications and emerging therapies. Literature searches were conducted in PubMed, Embase, and Cochrane databases through April 2026. Evidence quality was categorized according to study design, consistency of findings, and clinical applicability. Results: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1/gastric inhibitory polypeptide (GIP) dual agonists demonstrate substantial efficacy, with mean weight loss ranging from 5–10% with liraglutide to 21–26% with tirzepatide across various endpoints. These medications are recommended for individuals with a BMI ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with weight-related comorbidities. Common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), while serious complications are rare. Emerging therapies in development show promising efficacy profiles, with some triple agonists achieving > 20% weight loss in Phase 2 trials. Conclusions: Incretin-based OMMs represent an important therapeutic option when combined with lifestyle interventions. Appropriate patient selection, systematic monitoring, and proactive management of adverse events are essential for optimising outcomes. Ongoing research into novel agents, long-term safety data, and cardiovascular outcomes will continue to refine clinical practice. Implementation should be guided by shared decision-making, considering individual patient factors, preferences, and healthcare system resources.

  • Open Access

    International consensus on adolescent metabolic health: prevention of obesity and type 2 diabetes

    by Inass Shaltout, Peter Egbert Hermann Schwarz, Amr El-Meligi, Iman El Sherif, Hany Hammad, Shereen Abdelghaffar, Mona Hegazy, Gamela Nasr, Heba Habeeb, Engy Barakat, et al.

    Background: The global rise in adolescent obesity is driving an aggressive phenotype of type 2 diabetes (T2D), which is marked by rapid progression and premature mortality. Therefore, evidence-based, internationally applicable prevention guidelines are urgently needed. Methods: A multidisciplinary international panel ( n = 21) developed consensus recommendations through a systematic literature review (utilizing Web of Science, Scopus, PubMed, Cochrane, and EMBASE for the years 2000–2025) and a structured meeting process (held from October 2024 to December 2025). Consensus required ≥ 80% agreement. A total of eighty statements were initially proposed, from which sixty achieved preliminary agreement in Phase 1. Following iterative refinement in Phases 2 and 3, fifty achieved final consensus, and thirty were eliminated, either for failing to achieve 80% agreement or by being designated for further research. Results: The panel established fifty evidence-based recommendations across nine domains, which include screening, lifestyle intervention, school-based initiatives, digital health, therapeutic options, and policy. Key recommendations are to implement standardized screening protocols in schools, regulate the advertising of unhealthy foods and beverages, promote healthy lifestyle trends through media, and integrate artificial intelligence (AI) to tailor prevention plans. Conclusion: This consensus provides a practical, multisectoral framework for the global prevention of adolescent obesity and T2D, designed for application across healthcare, governmental, and non-governmental settings.


  • Open Access

    Safety considerations and adverse events associated with exercise across medical disciplines

    by Amin Roshdy Soliman, Gehad Maghraby, Farouk Mostafa Faris, Amany Abouzeid, Rabab Mahmoud Ahmed, Ebtesam Fahmy, Mona Hegazy, Alia A. Saleh, Shereen Abdelghaffar, Inass Shaltout

    Background: Exercise (Ex) is widely recommended across medical specialties as a core component of disease prevention and management. However, Ex prescription is frequently generalized, with limited consideration of disease-specific contraindications, baseline fitness, comorbidities, and potential adverse effects. This gap increases the risk of overlooked complications, particularly in patients with chronic, multisystem, or advanced disease. Methods: This narrative review synthesizes available evidence on Ex-related adverse effects across cardiovascular, respiratory, renal, hepatic, rheumatic, neurological, psychiatric, and endocrine, and pediatric conditions. Reported complications range from musculoskeletal injury and disease flares to serious events including arrhythmias, myocardial infarction, sudden cardiac death, exercise-induced hypertension, hypoglycemia, rhabdomyolysis, hypoxemia, bronchoconstriction, seizures, and neurovascular symptoms. Special populations including children, transplant recipients, patients with advanced organ failure, and those receiving anticoagulation or psychotropic therapy, exhibit narrower safety margins. Across specialties, adverse outcomes are inconsistently reported, contraindications are poorly defined, and high-risk patient groups are frequently excluded from clinical trials, limiting the generalizability of existing recommendations. Conclusion: Exercise is a powerful therapeutic intervention that requires individualized prescription to maximize benefits and minimize potential risks. Safe implementation depends on structured pre-exercise evaluation, condition-specific risk stratification, recognition of absolute and relative contraindications, appropriate supervision, and ongoing monitoring. A coordinated, multidisciplinary approach and improved communication between physicians and exercise professionals are essential to maximize benefit while minimizing harm. Further research is urgently needed to establish evidence-based, disease-specific exercise safety frameworks.

  • Open Access

    Non-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD)

    by Amin Roshdy Soliman, Rabab Mahmoud Ahmed, Amr Abdel Hady El Meligi, Ahmed Haroun Abdelmoaty, Mona A. Hegazy, Ahmed Saad, Sahar Alwakil, Nadine Alaa Sherif, Shereen Abdelghaffar, Ebtesam Fahmy, et al.

    Background: Non-diabetic hypoglycemia presents a substantial diagnostic challenge due to its diverse and often nonspecific symptomatology. The resultant delay in diagnosis can lead to a myriad of misdiagnoses. This misidentification not only prolongs patient suffering but also elevates the risk of severe complications, such as permanent neurologic damage and mortality. Recognizing the clinical nuances of non-diabetic hypoglycemia is paramount for timely and accurate diagnosis, which ultimately enhances patient outcomes and safety. Main Body: A position statement has been formulated by the Arabic Association for the Study of Diabetes and Metabolism (AASD) to address the complexities of diagnosing non-diabetic hypoglycemia. This statement highlights the challenges and pitfalls, covering key areas such as the vast spectrum of non-diabetic hypoglycemia within underreported subspecialties. It aims to elucidate the critical need for heightened clinical awareness and multidisciplinary management approaches to mitigate the profound impacts on patient health. Additionally, the statement provides guidance for overcoming barriers to optimal care. The team has distilled their experience into clinical algorithms to simplify information for healthcare professionals. Conclusion: Non-diabetic hypoglycemia is a rare condition that requires a comprehensive approach, including detailed history, medication review, and physical examination. Common pitfalls in diagnosis and management should be understood to avoid unnecessary evaluation and costs while avoiding misdiagnosis of patients with treatable or serious disorders.


  • Open Access

    Dietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD)

    by Amin Roshdy Soliman, Mona Hegazy, Rabab Mahmoud Ahmed, Shereen Abdelghaffar, Mohammed Gomaa, Sahar Alwakil, Dina Soliman, Lobna Sedky, Inass Shaltout

    Background: Diabetes is a significant global health concern. Regional factors play a crucial role in determining the appropriate diet for patients. Main body: The Arabic Association for the Study of Diabetes and Metabolism has developed a position statement that addresses the dietary needs of patients in the context of low income and cultural dietary habits. This statement aims to explore the most suitable diet for Middle East and North Africa (MENA) region and provide guidance for physicians to overcome barriers in optimal care. While most dietary guidelines focus on uncomplicated diabetes, it’s essential to recognize that diabetes often coexists with other common diseases in our region. Conclusion: International guidelines cannot be directly applied to the Egypt and Arab countries due to cultural and dietary differences. Our position statement shares valuable insights into managing diabetes in special situations and diverse clinical settings within this region. These recommendations are flexible, considering personal, cultural, and traditional differences.


  • Open Access

    Risk Stratification in People with Diabetes for Fasting During Ramadan: Consensus from Arabic Association for the Study of Diabetes and Metabolism

    by Inass Shaltout, Amr Mahmoud Abdelwahab, Amr El Meligi, Hany Hammad, Shereen Abdelghaffar, Atef Elbahry, Nasser Taha, Nehal Hamdy Elsaid, Amr Gad, Laila Hammouda, et al.

    Background: Current international guidelines recommend a pre-Ramadan risk assessment for people with diabetes (PwDM) who plan on fasting during the Holy month. However, a comprehensive risk assessment-based recommendation for the management of PwDM intending to fast is still controversial. Therefore, the Arabic Association for the Study of Diabetes and Metabolism (AASD) developed this consensus to provide further insights into risk stratification in PwDM intending to fast during Ramadan. Methods: The present consensus was based on the three-step modified Delphi method. The modified Delphi method is based on a series of voting rounds and in-between meetings of the expert panel to reach agreements on the statements that did not reach the consensus level during voting. The panel group comprised professors and consultants in endocrinology (both adult and pediatric). Other members included experts in the fields of cardiovascular medicine, nephrology, ophthalmology, and vascular surgery, affiliated with academic institutions in Egypt. Result: In PwDM who intend to fast during Ramadan, risk stratification is crucial to optimize patient outcomes and prevent serious complications. The present consensus provides risk assessment of those living with diabetes according to several factors, including the type of diabetes, presence, and severity of complications, number of fasting hours, and other socioeconomic factors. According to their risk factors, patients were classified into four categories (very high, high, moderate, and low risk). Conclusion: Future research is warranted due to the controversial literature regarding the impact of fasting on certain comorbidities.


  • Ramadan fasting in people with diabetes and chronic kidney disease (CKD) during the COVID-19 pandemic: The DaR global survey

    by Mohamed Hassanein, Sanobia Yousuf, Muhammad Yakoob Ahmedani, Alaa Albashier, Inass Shaltout, Alice Yong, Khadija Hafidh, Zanariah Hussein, Majd Aldeen Kallash, Naji Aljohani, et al.


  • The DAR 2020 Global survey: Ramadan fasting during COVID 19 pandemic and the impact of older age on fasting among adults with Type 2 diabetes

    by Mohamed Hassanein, Zanariah Hussein, Inass Shaltout, Wan Juani Wan Seman, Chin Voon Tong, Nurain Mohd Noor, Mehmet Akif Buyukbese, Lobna El Tony, Gamal Mohamed Shaker, Reem M. Alamoudi, et al.


  • Culturally based pre-Ramadan education increased benefits and reduced hazards of Ramadan fasting for type 2 diabetic patients

    by Inass Shaltout, Abir Zakaria, Amr Mahmoud Abdelwahab, AbdelKhalek Hamed, Nehal Hamdy Elsaid, Mazen Ahmed Attia

    Objectives In the current study, we aimed at evaluating the effect of a culturally-based pre-Ramadan education program (PREP) on glycemic control, weight, adherence to post-sunset physical activity, perception of hypoglycemia, and anti-diabetic medication dose adjustment during Ramadan fasting in type 2 diabetics. Study design A total of 1008 type 2 Diabetes patients were offered a culturally-based PREP in addition to the standard of care, two months before Ramadan. A retrospective interview one month after Ramadan compared the fasting experience of PREP attendees (470 patients) with those who merely received standard of care (538 patients) (Non-PREP). Results Ramadan fasting improved glycemic control with a correlation between HbA1c percent reduction and the number of fasting days (r = −0.290, p = 0.007). More HbA1c and weight percent reduction were observed in PREP attendees compared to the Non-PREP group (−14.8% ± 9.3 vs. -5.4% ± 5.4; p < 0.001; and − 1.96% ± 5.4 vs. -0.39% ± 2.8; p < 0.001, respectively). More commitment to night prayers in the PREP attendees compared to the Non-PREP group, (85.5% prayed >20 nights vs 28.4%; p < 0.001) with more HbA1c and weight percent reduction in the those who performed the prayers more than 20 nights compared to those who performed no prayers (−11.69% ± 8.8 vs −6.28% ± 6.4, p < 0.001; and − 2.76% ±5.1 vs 1.35% ±1.8, p < 0.001, respectively). More perception of true hypoglycemia was associated with PREP attendance (p0.046), insulin treatment (p0.000), and reduction of antidiabetic medication dosage (p0.004). Repeated lowering of antidiabetic medications doses with sequential downsizing of meals’ portions, and appetite was reported. Conclusion Ramadan fasting was beneficial for people with type 2 diabetes with reduction of HbA1c in correlation with the number of fasting days. Contrasting PREP with Non-PREP participants discovered better HbA1c and weight reduction in the former group even with equal number of fasting days. PREP participants performed more Taraweeh night prayers. The more the prayer nights the more decline of HbA1c and weight was observed. PREP improved perception and response to hypoglycemia with low-dosing of antidiabetic medications, especially insulin.